All In Biotech

NDA 022567 · Abbvie

Viibryd

Vilazodone Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jan 21, 2011

Approved uses

3

Original approval plus efficacy supplements

Registered trials

33

12 Phase 3, 1 recruiting

FAERS reports

9,233

3,618 serious, 188 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavi ors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . V IIBRYD is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Viibryd is not approved for use in pediatric patients ( 8.4 ).

What it is approved for

From the label in effect Oct 1, 2023.

VIIBRYD ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. VIIBRYD is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).

Mechanism: The mechanism of action of vilazodone in the treatment of major depressive disorder is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT 1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • VIIBRYD · VILAZODONE HYDROCHLORIDE 10MG · TABLET, ORAL · Prescription · TE AB
  • VIIBRYD · VILAZODONE HYDROCHLORIDE 20MG · TABLET, ORAL · Prescription · TE AB
  • VIIBRYD · VILAZODONE HYDROCHLORIDE 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Vilazodone" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,096
  • nausea786
  • diarrhoea783
  • anxiety635
  • insomnia620
  • drug ineffective566
  • headache544
  • depression492
  • dizziness485
  • fatigue463
  • suicidal ideation417
  • feeling abnormal402

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
2011460
20121,132
2013738
2014524
2015444
2016880
2017736
2018562
2019743
2020829
2021562
2022484
2023380
2024296
2025279
2026183

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Viibryd (Vilazodone HCl)

2024 spending

$6.0M

Beneficiaries

3,238

13,120 claims

Per beneficiary

$1,848

$11.06 per unit

View as table
YearSpending
2020$125,109,998
2021$134,672,680
2022$86,482,099
2023$17,377,041
2024$5,984,796

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.